Investigational drug · Phase 3
calcineurin inhibitors
Not approved by FDA. In 2 industry-sponsored Phase 2 or 3 trials that are active or finished in the last two years, most often for Dermatitis Atopic.
Phase 3Last checked: Nov 20, 2026Latest source record: Oct 13, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 3
Industry-sponsored trials
Phase 2 and 3 trials
2
1 still active
All registered trials
288
Any phase or sponsor naming "calcineurin inhibitors"
First trial start
2022
Aug 22, 2022
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "calcineurin inhibitors", any sponsor or status.
Conditions studied
As listed on its trial records.
- Dermatitis Atopic
Approved drugs for the same conditions: Dermatology
Largest trials
Live from ClinicalTrials.gov: studies naming "calcineurin inhibitors" as an intervention, largest first.
- Advancing Renal TRANSplant eFficacy and Safety Outcomes With an eveRolimus-based regiMen (TRANSFORM)Pivotal-lookingCompleted
Novartis PharmaceuticalsNovartis (NVS)
NCT01950819 · 2,037 participants · Start Dec 3, 2013 · Primary completion Feb 1, 2017
Drug: Induction therapy; Corticosteroids and 2 more · For: End Stage Renal Disease (ESRD); Chronic Kidney Disease (CKD); Hemodialysis and 2 more
Sites: Birmingham, Alabama; Loma Linda, California; Los Angeles, California · 184 sites in all
- Long-Term Safety and Efficacy Evaluation of Amlitelimab in Participants of Previous Amlitelimab Moderate to Severe Atopic Dermatitis Clinical TrialsPivotal-lookingActive, not recruiting
SanofiSanofi (SNY)
NCT05492578 · 1,856 participants · Start Aug 22, 2022 · Primary completion Jan 22, 2029
Drug: Amlitelimab; Topical corticosteroids and 2 more · For: Dermatitis Atopic
Sites: Birmingham, Alabama; Scottsdale, Arizona; Tucson, Arizona · 392 sites in all
GlaxoSmithKlineGSK (GSK)
NCT01914770 · 1,016 participants · Start Jul 2009 · Primary completion Nov 2010
Drug: Belimumab 1 mg/kg; Belimumab 10 mg/kg and 1 more · For: Systemic Lupus Erythematosus
- Campath, Calcineurin Inhibitor Reduction and Chronic Allograft NephropathyPivotal-lookingCompleted
University of OxfordAcademic, hospital or other
NCT01120028 · 852 participants · Start Sep 2010 · Primary completion Feb 2014
Drug: Alemtuzumab; Basiliximab and 2 more · For: Kidney Transplantation
Sites: Oxford, United Kingdom; Birmingham, United Kingdom; Cambridge, United Kingdom · 20 sites in all
- Study Comparing Conversion to Sirolimus vs. Continued Use of Calcineurin Inhibitors in Kidney Transplant RecipientsPivotal-lookingCompleted
Wyeth is now a wholly owned subsidiary of PfizerPfizer (PFE)
NCT00038948 · 830 participants · Start Jan 2002 · Primary completion May 2008
Drug: Sirolimus; tacrolimus and 1 more · For: Renal Transplantation
- Efficacy, Safety and Evolution of Cardiovascular Parameters in Renal Transplant RecipientsPivotal-lookingCompleted
Novartis PharmaceuticalsNovartis (NVS)
NCT01114529 · 828 participants · Start Aug 9, 2010 · Primary completion Oct 30, 2014
Drug: Everolimus; Prograf or Neoral · For: Kidney Transplantation
Sites: CABA, Argentina; San Martín, Argentina; Resistencia, Argentina · 77 sites in all
- Study Investigating a Standard Regimen in de Novo Kidney Transplant Patients Versus a Calcineurin Inhibitor (CNI)-Free Regimen and a CNI-low Dose RegimenPivotal-lookingCompleted
Novartis PharmaceuticalsNovartis (NVS)
NCT00514514 · 802 participants · Start Jul 2007 · Primary completion Jun 2015
Drug: Everolimus; Myfortic and 2 more · For: Kidney Transplantation
Sites: Aachen, Germany; Berlin, Germany; Cologne, Germany · 18 sites in all
- Assessment of Biomarker-Guided CNI Substitution In Kidney TransplantationPivotal-lookingRecruiting
National Institute of Allergy and Infectious Diseases (NIAID)NIH
NCT05917522 · 800 participants (planned) · Start Dec 7, 2023 · Primary completion Jul 2027
Drug: Abatacept · For: Kidney Transplant
Sites: Birmingham, Alabama; Los Angeles, California; New Haven, Connecticut · 15 sites in all
Bristol-Myers SquibbBristol Myers Squibb (BMY)
NCT01656343 · 775 participants · Start Oct 31, 2011 · Primary completion Aug 5, 2019
Drug: Calcineurin inhibitors (CNI); Belatacept · For: Kidney Transplantation; Transplantation, Kidney
- A Study Assessing Rocatinlimab in Combination With Topical Corticosteroid and/or Topical Calcineurin Inhibitors in Adult Participants With Moderate-to-severe Atopic Dermatitis (AD)Pivotal-lookingCompleted
AmgenAmgen (AMGN)
NCT05724199 · 746 participants · Start Feb 21, 2023 · Primary completion Sep 15, 2024
Drug: Rocatinlimab · For: Atopic Dermatitis
Sites: Birmingham, Alabama; Phoenix, Arizona; Sun City West, Arizona · 234 sites in all
Newest research
PubMed records naming it or its code names, newest first.
- All About the Meds: Contraception, Infertility, and Immunosuppression in Reproductive-aged Female Transplant Recipients.
Katz-Greenberg G, Rossi AP, Afshar Y, et al. · Transplantation 2026
- Swiss Practice Recommendations for Chronic Prurigo Including Prurigo Nodularis.
Mueller SM, Beltraminelli H, Boehncke WH, et al. · Int J Dermatol 2026
- Predictive value of CD44 in membranous nephropathy with focal segmental glomerular sclerosis lesions treated with calcineurin inhibitors.
He HG, Huang YY, Ye K, et al. · Ren Fail 2026
- Local therapeutic strategies for neurocutaneous dysesthesia: from capsaicin to cannabinoids.
Logger J, Kallewaard JW, Visscher R, et al. · J Dermatolog Treat 2026
- Treatment of discoid lupus erythematosus with crisaborole.
Dai Y, Song D, Liu H, et al. · J Dermatolog Treat 2026
- Tacrolimus in Solid Organ Transplantation: Historical Impact, Current Use, and Future Directions in Immunosuppression.
Dieter R, Jaffe IS, Mattoo A · J Pharm Pract 2026
Also in development for Dermatitis Atopic
- AmlitelimabSAR445229Phase 39 trials
Sanofi · Dermatitis Atopic, Coeliac Disease, Celiac Disease
- LunsekimigSAR443765Phase 39 trials
Sanofi · Asthma, Chronic Obstructive Pulmonary Disease, Chronic Rhinosinusitis With Nasal Polyps
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do. More from Sanofi.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.